Marco Winzer
Partner
About me
| Team | Life Sciences & Chemistry, Partner |
| at HTGF since | 2005 |
CV
Marco Winzer has been with High-Tech Gründerfonds since its foundation and has helped to establish the fund. The economics graduate has many years of experience in financing start-ups in the life sciences industry and has supported a number of start-ups all along the value chain of the ‘Venture Capital Model’ – from seed financing to successful exit. Before working for HTGF, the Partner acquired expertise in consulting start-ups and held various positions at the Business Innovation Center Kaiserslautern as well as the Technologie-Beteiligungsgesellschaft and development bank KfW.
My success stories in the HTGF portfolio
Reactive Robotics is a leading healthcare startup dedicated to developing innovative technologies and solutions for the healthcare industry. The company is on a mission to revolutionize healthcare by integrating technology …
To the complete profileof Reactive Robotics
Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients’ vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by …
To the complete profileof Preventicus
AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biologic drugs in acute vascular syndromes and have completed phase 2.
To the complete profileof AdvanceCOR
Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for …
To the complete profileof Zedira
In recent years, the IoT (Internet of Things) market has developed dynamically. New vendors brought new products in the fields of sensors, connectivity, applications and analytics to the market. Exelonix …
To the complete profileof exelonix
CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.
To the complete profileof CorTec
Guided to exit
Exit
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs. Exit since …
To the complete profileof Corimmun
Exit
UroTec’s MukoCell® made of autologous, in vitro cultured mucosa cells. Only a small biopsy needs to be taken from the patient. Exit since August 2010.
To the complete profileof UROTEC
Exit
SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A …
To the complete profileof SIRION Biotech
Exit
m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated …
To the complete profileof m2p-labs
Exit
futalis provides personalized petfood for dogs. To prevent health issues caused by feeding mistakes, each individual dog is offered a veterinary diet calculation. Based on scientific criteria, the nutritional requirements …
To the complete profileof futalis
Exit
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …
To the complete profileof c-LEcta
Recent posts
Zum Artikel
Reactive Robotics: Staying on Course for Growth in the MedTech Sector with a €5 Million investment
Zum Artikel
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharmato Develop First-in-Class Celiac Disease Therapy
Zum Artikel
Successful Exit for Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW – PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
Zum Artikel
Social Media & contact
LinkedIn
Marco Winzer
Profil